Head to Head Survey: Inhibrx Biosciences (NASDAQ:INBX) & CollPlant Biotechnologies (NASDAQ:CLGN)

CollPlant Biotechnologies (NASDAQ:CLGN) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings.

Valuation and Earnings

This table compares CollPlant Biotechnologies and Inhibrx Biosciences”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CollPlant Biotechnologies	$2.37 million	3.37	-$16.61 million	($1.02)	-0.61
Inhibrx Biosciences	$1.30 million	656.21	-$140.05 million	($9.04)	-6.46

CollPlant Biotechnologies has higher revenue and earnings than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than CollPlant Biotechnologies, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

CollPlant Biotechnologies has a beta of 3.02, indicating that its share price is 202% more volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500.

Insider & Institutional Ownership

21.7% of CollPlant Biotechnologies shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 9.6% of CollPlant Biotechnologies shares are held by company insiders. Comparatively, 17.1% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current recommendations for CollPlant Biotechnologies and Inhibrx Biosciences, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CollPlant Biotechnologies	1	1	1	0	2.00
Inhibrx Biosciences	1	2	0	0	1.67

CollPlant Biotechnologies presently has a consensus target price of $11.50, suggesting a potential upside of 1,743.84%. Given CollPlant Biotechnologies’ stronger consensus rating and higher probable upside, equities research analysts clearly believe CollPlant Biotechnologies is more favorable than Inhibrx Biosciences.

Profitability

This table compares CollPlant Biotechnologies and Inhibrx Biosciences’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CollPlant Biotechnologies	-353.70%	-142.82%	-100.25%
Inhibrx Biosciences	N/A	-269.56%	-71.94%

Summary

CollPlant Biotechnologies beats Inhibrx Biosciences on 9 of the 14 factors compared between the two stocks.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

About Inhibrx Biosciences

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.